Published in Cell Rep on February 25, 2016
Regulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic Mechanisms. Front Genet (2016) 0.77
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta (2017) 0.76
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics (2017) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer. Am J Transl Res (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Prediction of mammalian microRNA targets. Cell (2003) 53.70
The epigenomics of cancer. Cell (2007) 30.91
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol (2003) 5.27
DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol (2005) 5.02
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell (2014) 3.17
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res (2003) 2.37
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev (2007) 2.34
Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 2.28
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet (2013) 1.94
Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis (2006) 1.85
Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature (2015) 1.74
Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res (2006) 1.73
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell (2015) 1.70
Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene (2007) 1.70
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology (2001) 1.67
mTOR is activated in the majority of malignant melanomas. J Invest Dermatol (2007) 1.66
DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer (2008) 1.60
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55
An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem (2002) 1.48
Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol (2006) 1.35
DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res (2009) 1.33
Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell (2010) 1.31
Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci U S A (2011) 1.26
Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer (2010) 1.23
CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Gut (2012) 1.17
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol (2000) 1.12
A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding. Mol Cancer Res (2009) 1.10
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
MiR-424/503-mediated Rictor upregulation promotes tumor progression. PLoS One (2013) 1.02
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS One (2012) 0.99
MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem (2012) 0.96
TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation? Curr Opin Genet Dev (2005) 0.96
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Res (2015) 0.95
Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. Mol Cancer (2013) 0.94
In epigenetic therapy, less is more. Cell Stem Cell (2012) 0.93
DNA methylation as a target of epigenetic therapeutics in cancer. Anticancer Agents Med Chem (2013) 0.92
Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol (2003) 0.90
Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res Treat (2011) 0.86
Acute depletion redefines the division of labor among DNA methyltransferases in methylating the human genome. Cell Rep (2014) 0.85
Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma. Biochim Biophys Acta (2014) 0.83
Developing melanoma therapeutics: overview and update. Wiley Interdiscip Rev Syst Biol Med (2013) 0.82
Transcriptional and post-transcriptional control of DNA methyltransferase 3B is regulated by phosphatidylinositol 3 kinase/Akt pathway in human hepatocellular carcinoma cell lines. J Cell Biochem (2010) 0.79
Postnatal lineage mapping of follicular melanocytes with the Tyr::CreER(T) (2) transgene. Pigment Cell Melanoma Res (2012) 0.78
Significance of DNMT3b in oral cancer. PLoS One (2014) 0.76